![[object Object],[object Object],[object Object],[object Object],[object Object],Introduction to case Outline](data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7)
Recomendados
Recomendados
Mais conteúdo relacionado
Mais procurados
Mais procurados (15)
Destaque
Destaque (8)
Semelhante a Genentech's capacity expansion options to meet growing demand for cancer drug Avastin
Semelhante a Genentech's capacity expansion options to meet growing demand for cancer drug Avastin (20)
Último
Último (20)
Genentech's capacity expansion options to meet growing demand for cancer drug Avastin
- 1. Slide
- 5. Slide
- 6. Slide 2005 Most Admired Biotech Company
- 8. 1AVASTIN : drug for patients with previously untreated metastatic cancer of the colon or rectum Slide Overview Mission To be the leading biotechnology company, using human genetic information to discover, develop, manufacture and commercialize biotherapeutics that address significant unmet medical needs. In 2003 Revenues : $3,300 million 79 % from product sales Net Income: $563 million In 2004 AVASTIN 1 was approved by FDA First nine months of 2004 sales of AVASTIN 15 % or $2,684,000 million TARCEVA & OMNITARG both drugs that Genentech promise to launch in the next year
- 9. Genentech Product Information (2001-2003) Slide ($ in millions)
- 13. Production Process Slide
- 14. Manufacturing Process Flow Chart (per Batch) Slide 2,000L 12,000L ( 0.75gm/L )
- 15. Slide Ultra Filtration Frozen Bulk Packaged Products
- 17. Slide
- 23. A model for all cancer indication Slide
- 24. Slide Capacity Planning Demand-upside Demand-Basecase Demand- Downside Sample Capacity Requirements Chart
- 25. Slide Plan Economic optimum a Total Product Demand (kilograms) Distribution of Possible Demand Scenerios
- 28. Plant Size and Design Slide
- 29. Conclusion Slide
- 30. Slide